Heteroaryloxy quinazoline derivatives

Abstract

Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R 1 represents a group of a formula: (wherein R 11 and R 12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R 2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

1 - 17 . (canceled) 
     
     
         18 . A compound represented by a formula (I): 
       
         
           
           
               
               
           
         
         wherein the A ring represents a pyrimidinyl group, which may have one or two groups selected from the group consisting of lower alkyl, lower alkoxy, halogen, hydroxy, C 3-7  cycloalkyl and lower alkyl having 1-3 identical or different lower alkoxy groups, halogen atoms or hydroxy groups; 
         the B ring represents a 5- or 6-membered heteroaryl group having 1-3 identical or different hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms; 
         R represents a group selected from the group consisting of lower alkyl, lower alkoxy, halogen, hydroxy and lower alkyl having 1-3 identical or different lower alkoxy groups, halogen atoms or hydroxy groups; 
         k represents an integer of from 0 to 3; 
         R 1  denotes a group represented by a formula (II-1), (II-2), (II-3) or II-4): 
       
       
         
           
           
               
               
           
         
         wherein R 11  and R 12  each independently represent hydrogen, lower alkyl or C 3-7  cycloalkyl, or R 11  and R 12 , together with the nitrogen atom to which they are bound, constitute 4- to 7-membered nitrogen-containing aliphatic rings (which may be substituted with 1-3 identical or different halogen atoms), or any carbon atom of (CH 2 ) m , together with R 11  or R 12 , may constitute 4- to 7-membered nitrogen-containing aliphatic rings; 
         any carbon atom in (CH 2 ) m  may be substituted with a lower alkyl group; 
         the nitrogen atom to which R 11  and R 12  are bound may form N-oxide; and 
         m represents an integer of from 2 to 6, 
         a group represented by a formula (II-2)
   —O—(CH 2 ) n —R 13   (II-2)
 
 
       
       wherein:
 R 13  represents lower alkoxy, hydroxy or carboxyl; 
 n represents an integer of from 1 to 6; 
 upon R 13  being lower alkoxy; the lower alkoxy, together with any carbon atom of (CH 2 ) n , may form 5- to 7-membered aliphatic rings; and any carbon atom in (CH 2 ) n  may be substituted with a lower alkyl group), 
 a group represented by a formula (II-3) 
 
       
         
           
           
               
               
           
         
         wherein R 14  and R 15  are synonymous with the above R 11  and R 12 ; 
         p represents an integer of from 2 to 6; and 
         R 3  represents a hydrogen atom or a lower alkyl group, or a group represented by a formula (II-4) 
       
       
         
           
           
               
               
           
         
         wherein: 
         R 16  and R 17  are synonymous with the above R 11  and R 12 ; 
         q represents an integer of from 2 to 6; and 
         R 4  represents a hydrogen atom or a lower alkyl group, 
         R 2  is a group selected from the group consisting of: lower alkyl, lower alkoxy, halogen, hydroxy, cyano, carboxyl, alkoxycarbonyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, lower alkylsulfonyl and lower alkyl having 1-3 identical or different lower alkoxy groups, halogen atoms, hydroxy groups, cyano groups, carboxyl groups, alkoxycarbonyl groups, N-alkylcarbamoyl groups, N,N-dialkylcarbamoyl groups or lower alkylsulfonyl groups, and 
         r represents an integer of from 0 to 3, 
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         19 . The compound according to claim  1  wherein the B ring is a group selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiadiazolyl, imidazolyl and isoxazolyl groups, or a pharmaceutically acceptable salt thereof. 
     
     
         20 . The compound according to  claim 18  wherein R 1  is a group represented by the formula (II-1) or (II-2), or a pharmaceutically acceptable salt thereof. 
     
     
         21 . The compound according to  claim 18  wherein R 1  is a group represented by the formula (II-1), or a pharmaceutically acceptable salt thereof. 
     
     
         22 . The compound according to  claim 18  wherein R 1  is a group represented by the formula (II-2), or a pharmaceutically acceptable salt thereof. 
     
     
         23 . The compound according to  claim 18  wherein R 1  is a group represented by the formula (II-3), or a pharmaceutically acceptable salt thereof. 
     
     
         24 . The compound according to  claim 18  wherein R 1  is a group represented by the formula (II-4), or a pharmaceutically acceptable salt thereof. 
     
     
         25 . The compound according to  claim 21 , wherein one of R 11  and R 12  is a hydrogen atom; and the other is a lower alkyl or C 3-7  cycloalkyl group, or a pharmaceutically acceptable salt thereof. 
     
     
         26 . The compound according to  claim 21 , wherein R 11  and R 12  each independently are lower alkyl or C 3-7  cycloalkyl groups, or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The compound according to  claim 21 , wherein R 11  and R 12  represent 4- to 7-membered nitrogen-containing aliphatic rings formed by R 11  and R 12  together with the nitrogen atom to which they are bound, (the nitrogen atom to which R 11  and R 12  are bound may form N-oxide; and the 4- to 7-membered nitrogen-containing aliphatic rings may be substituted with 1-3 identical or different halogen atoms), or a pharmaceutically acceptable salt thereof. 
     
     
         28 . The compound according to  claim 21 , wherein R 11  and R 12  represent 4- to 7-membered nitrogen-containing aliphatic rings formed by either R 11  or R 12  together with any carbon atom of (CH 2 ) m  (any carbon atom in (CH 2 ) m  may be substituted with a lower alkyl group), or a pharmaceutically acceptable salt thereof. 
     
     
         29 . The compound according to  claim 18 , wherein the compound represented by the formula (I) is:
 6-({3-chloro-5-[2-(methylamino)ethoxy]pyridin-2-yl}oxy)-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   6-({5-[2-(dimethylamino)ethoxy]-3-methylpyridin-2-yl}oxy)-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   6-({3-fluoro-5-[2-(methylamino)ethoxy]pyridin-2-yl}oxy)-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   6-({3-fluoro-5-[2-(isopropylamino)ethoxy]pyridin-2-yl}oxy)-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   6-({3-methyl-5-[2-(methylamino)ethoxy]pyridin-2-yl}oxy)-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   6-{[3-chloro-5-(3-pyrrolidin-1-ylpropoxy)pyridin-2-yl]oxy}-N-(5-methylpyrazin-2-yl)quinazolin-4-amine,   
       or a pharmaceutically acceptable salt thereof. 
     
     
         30 . A pharmaceutical composition comprising the compound according to  claim 18  or the pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier. 
     
     
         31 . The composition of  claim 30  which further comprises another active ingredient intended for the treatment of type II diabetes. 
     
     
         32 . A method of treating diabetes in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with  claim 18 , or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat diabetes.